11 completed, 4 unknown, 3 active not recruiting, 3 not yet recruiting. 28 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 28 | Completed 11, Unknown 4, Active not recruiting 3, Not yet recruiting 3, Terminated 3, Recruiting 2, Withdrawn 2 |
Follow Hematologic Neoplasms: new trials by email Literature Review of Hematologic Neoplasms trials Research Report on Hematologic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MACE and BTK Inhibitors ibrutinib, Acalabrutinib, Zanubrutinib - Hematologic Cancer, MACE | Phase 4 | Not yet recruiting | University Hospital, Caen | 10000 | 2026-12-01 | 2026-11-06 |
| Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera Ropeginterferon alfa-2b, Phlebotomy and aspirin - Polycythemia Vera, Myeloproliferative Neoplasm | Phase 4 | Withdrawn | PharmaEssentia | 2026-08-01 | 2026-07-31 | |
| Early Discontinuation of Antibiotics in Paediatric High-risk Febrile Neutropenia Early Discontinuation of Antibiotics, Standard Antibiotic Continuation Strategy - Febrile Neutropenia (FN), Pediatric Cancer | Phase 4 | Not yet recruiting | Hospital Universitari Vall d'Hebron Research Institute | 136 | 2026-06-01 | 2026-05-15 |
| Allergy Delabeling in Antibiotic Stewardship - Intervention RENEW-IN Algorithm for assessment of a beta-lactam intervention, EMR Review - Beta Lactam Allergy, Hematologic Malignancy | Phase 4 | Recruiting | Abramson Cancer Center at Penn Medicine | 3800 | 2026-04-20 | 2026-06-17 |
| Individualized First Maintenance Doses of Voriconazole Through a Multiparametric Algorithm Individualization of first voriconazole maintenance doses - Aspergillosis Invasive, Fungal Infection | Phase 4 | Not yet recruiting | University Hospital, Grenoble | 30 | 2024-10-01 | 2024-09-03 |
| Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors Hydroxyurea - Polycythemia Vera | Phase 4 | Terminated | Novartis Pharmaceuticals | 76 | 2023-07-28 | 2026-08-18 |
| Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation Ceftolozane / Tazobactam Injection - Pneumonia, Hematologic Malignancy | Phase 4 | Terminated | Weill Medical College of Cornell University | 17 | 2023-01-10 | 2026-01-21 |
| CEFtolozane-Tazobactam for the Empiric Anti-bacterial Treatment of Neutropenic Fever in Hematology Patients Ceftolozane-tazobactam IV - Neutropenia, Febrile, Hematologic Cancer | Phase 4 | Withdrawn | Hamad Medical Corporation | 2022-08-01 | 2023-08-14 | |
| Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome Pegloticase, Rasburicase - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 4 | Completed | M.D. Anderson Cancer Center | 10 | 2022-04-05 | 2026-05-06 |
| Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults Biological samples - Kidney Transplant, Myeloma | Phase 4 | Completed | Centre Hospitalier Régional d'Orléans | 196 | 2021-03-26 | 2025-12-23 |
| Efficacy and Safety of Micafungin for Injection in Prevention and Treatment of Fungal Infection in Hematological Tumors Micafungin Sodium - Hematological Tumors Patients With High Risk Factors of Invasive Fungal Disease | Phase 4 | Unknown | Shandong Provincial Hospital | 230 | 2021-02-01 | 2021-02-04 |
| Effect of Opioid Infusion Rate on Abuse Liability Potential of Intravenous Hydromorphone for Cancer Pain Hydromorphone, Placebo Administration, Questionnaire Administration - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 4 | Active not recruiting | M.D. Anderson Cancer Center | 84 | 2020-09-10 | 2026-06-16 |
| RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma RDD, VDD - Hematologic Neoplasms, Multiple Myeloma | Phase 4 | Unknown | Shandong Provincial Hospital | 120 | 2019-03-30 | 2019-11-29 |
| Ketamine-ketorolac Versus Fentanyl- Ketorolac I.M in Children During Bone Marrow Biopsy ketamine-ketorolac, fentanyl- ketorolac - Hematological Malignancy (Leukemia- Lymphoma) | Phase 4 | Completed | Mansoura University | 80 | 2018-08-26 | 2020-09-09 |
| Gardasil 9 Vaccine in Preventing HPV Infection in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant Recombinant Human Papillomavirus Nonavalent Vaccine - Allogeneic Hematopoietic Stem Cell Transplant Recipient, Hematopoietic and Lymphoid Cell Neoplasm | Phase 4 | Active not recruiting | M.D. Anderson Cancer Center | 48 | 2017-04-23 | 2026-07-16 |
| A Study Comparing the Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Participants With Hematological Malignancy Itraconazole, Caspofungin - Hematologic Neoplasms | Phase 4 | Terminated | Xian-Janssen Pharmaceutical Ltd. | 61 | 2016-11-30 | 2019-05-06 |
| Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease Bortezomib, Eltrombopag, Imatinib - Hematological Neoplasms | Phase 4 | Recruiting | Wei Zhao | 1500 | 2016-01-31 | 2025-03-30 |
| A Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation Tropisetron, Dexamethasone, Aprepitant - Vomiting | Phase 4 | Unknown | Jun Zhu | 130 | 2015-10-01 | 2016-12-30 |
| CINC424A2X01B Rollover Protocol ruxolitinib, panobinostat - Primary Myelofibrosis, Polycythemia Vera | Phase 4 | Active not recruiting | Novartis Pharmaceuticals | 279 | 2015-03-05 | 2026-10-19 |
| Short Versus Extended Antibiotic Treatment With a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients With FUO Discontinuation of imipenem-cilastatin or meropenem - Febrile Neutropenia, Hematological Malignancy | Phase 4 | Completed | Amsterdam UMC, location VUmc | 276 | 2014-12-01 | 2019-09-25 |
Showing 20 of 28. Sign in to see all of them.
Febrile Neutropenia (3) · Neoplasms (3) · Polycythemia Vera (3) · Invasive Fungal Infections (2) · Lymphoma (2) · Mycoses (2) · Myeloproliferative Disorders (2) · Neoplasms, Plasma Cell (2) · Neutropenia (2) · Acquired Immunodeficiency Syndrome (1) · Bacteremia (1) · Bronchiolitis Obliterans Syndrome (1) · Diabetes Mellitus, Type 2 (1) · Fever (1)
Hematologic Diseases (28) · Hemic and Lymphatic Diseases (28) · Neoplasms by Site (28) · Neoplasms (25) · Infections (7) · Immune System Diseases (6) · Bacterial Infections and Mycoses (5) · Immunoproliferative Disorders (5) · Neoplasms by Histologic Type (5) · Pathological Conditions, Signs and Symptoms (5) · Bone Marrow Diseases (4) · Lymphoproliferative Disorders (4) · Agranulocytosis (3) · Bone Marrow Neoplasms (3) · Cytopenia (3)
Itraconazole (2) · Meropenem (2) · ceftolozane, tazobactam drug combination (2) · Amides (1) · Amikacin (1) · Anti-Infective Agents (1) · Aprepitant (1) · Aspirin (1) · Blood Specimen Collection (1) · Bortezomib (1) · Busulfan (1) · Carbamates (1) · Caspofungin (1) · Cefepime (1) · Ceftazidime (1)
M.D. Anderson Cancer Center (4) · Novartis Pharmaceuticals (2) · Shandong Provincial Hospital (2) · Abramson Cancer Center at Penn Medicine (1) · Amsterdam UMC, location VUmc (1) · Centre Hospitalier Régional d'Orléans (1) · Eli Lilly and Company (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Hamad Medical Corporation (1) · Hospital Clinic of Barcelona (1) · Hospital Universitari Vall d'Hebron Research Institute (1) · Jens Rikardt Andersen (1) · Johns Hopkins University (1) · Jun Zhu (1) · Mansoura University (1)
United States (9) · China (6) · France (4) · Spain (3) · Belgium (2) · Germany (2) · Australia (1) · Bulgaria (1) · Canada (1) · Chile (1) · Denmark (1) · Egypt (1) · Greece (1) · Hungary (1) · India (1)
Ali S. Omrani, FRCP (1) · Anca Colita, MD (1) · Gautier-Veyret Elodie (1) · He Huang, MD (1) · Janelle Perkins, PharmD (1) · Jens Rikardt Andersen, MD,MPA (1) · Jessica P Hwang (1) · Joseph A Arthur, MD (1) · Jun Zhu, MD (1) · Kieren Marr, MD (1) · Kim Vanstraelen, PharmD (1)
PMID 22198540, PMID 22927454, PMID 34240339, PMID 35691326, PMID 38497347, PMID 39115709
2014 (2)